AxoGen, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of AxoGen, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Medical Devices
Multiples of its companies with a market value at most 60 days old, times AxoGen, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | AxoGen, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 1.2× / 2.3× / 3.3× | 11.1× | revenue $225 M | $273 M to $748 M | 36 |
| Price to book | 1.4× / 2.6× / 4.1× | 23.0× | book equity $129 M | $182 M to $523 M | 36 |
Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.
Against its own history
AxoGen, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
Price to sales
11.8×Now above its median of 5.2×, in the top quarter of its range; range 2.1× to 11.8× over 27 months.
Price to book
23.0×Now above its median of 8.0×, in the top quarter of its range; range 2.9× to 23.0× over 27 months.
as of Oct 30, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 30, 2026.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $225 M | $-16 M | $1 M | $4 M | $-3 M | $13 M | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $187 M | $-10 M | $5 M | $3 M | $1 M | $20 M | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $159 M | $-22 M | $-6 M | $14 M | $-20 M | $16 M | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $139 M | $-29 M | $-16 M | $20 M | $-36 M | $30 M | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $127 M | $-27 M | $-13 M | $28 M | $-41 M | $12 M | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $112 M | $-24 M | $-10 M | $22 M | $-32 M | $-17 M | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value $3.0 B on Oct 30, 2026.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.